NASDAQ:GRTSGritstone Oncology Stock Price, Forecast & News

Gritstone Oncology's stock was trading at $6.67 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GRTS shares have decreased by 2.1% and is now trading at $6.53. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone Oncology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gritstone Oncology.

Gritstone Oncology is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Gritstone Oncology.

Gritstone Oncology Inc (NASDAQ:GRTS) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.73) by $0.02. The firm earned $1.26 million during the quarter, compared to the consensus estimate of $1.20 million. Gritstone Oncology had a negative net margin of 2,397.90% and a negative return on equity of 69.76%. View Gritstone Oncology's earnings history.

3 equities research analysts have issued 12 month price targets for Gritstone Oncology's shares. Their forecasts range from $17.00 to $17.00. On average, they anticipate Gritstone Oncology's stock price to reach $17.00 in the next year. This suggests a possible upside of 160.3% from the stock's current price. View analysts' price targets for Gritstone Oncology.

News stories about GRTS stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gritstone Oncology earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutGritstone Oncology.

Some companies that are related to Gritstone Oncology include Krystal Biotech (KRYS), Cellectis (CLLS), Avrobio (AVRO), BioCryst Pharmaceuticals (BCRX), Nantkwest (NK), Replimune Group (REPL), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (RCEL), Vericel (VCEL), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Oyster Point Pharma (OYST), Aptose Biosciences (APTO), Agenus (AGEN) and Atara Biotherapeutics (ATRA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone Oncology investors own include Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Amarin (AMRN), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Advanced Micro Devices (AMD) and Axsome Therapeutics (AXSM).

(GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

Gritstone Oncology trades on the NASDAQ under the ticker symbol "GRTS."

Gritstone Oncology's stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (8.23%), Casdin Capital LLC (6.09%), BlackRock Inc. (5.88%), Victory Capital Management Inc. (0.95%), Victory Capital Management Inc. (0.94%) and Ensign Peak Advisors Inc (0.94%). Company insiders that own Gritstone Oncology stock include Nicholas Simon and Raphael Rousseau. View institutional ownership trends for Gritstone Oncology.

GRTS stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Ensign Peak Advisors Inc, UBS Group AG, Victory Capital Management Inc., Victory Capital Management Inc., and First Trust Advisors LP. View insider buying and selling activity for Gritstone Oncology.

GRTS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Casdin Capital LLC, Russell Investments Group Ltd., Squarepoint Ops LLC, Geode Capital Management LLC, JPMorgan Chase & Co., Nuveen Asset Management LLC, and Alliancebernstein L.P.. View insider buying and selling activity for Gritstone Oncology.

Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GRTS stock can currently be purchased for approximately $6.53.

Gritstone Oncology has a market capitalization of $243.34 million and generates $4.36 million in revenue each year. The company earns $-94,430,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. Gritstone Oncology employs 113 workers across the globe.

The official website for Gritstone Oncology is www.gritstoneoncology.com.

Gritstone Oncology's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company can be reached via phone at 510-871-6100 or via email at www.gritstoneoncology.com.